171 related articles for article (PubMed ID: 24351434)
1. Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda-Gotor J; González-Juanatey C; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2014; 32(2):218-24. PubMed ID: 24351434
[TBL] [Abstract][Full Text] [Related]
2. Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoietin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Arias-Bajo M; Rueda-Gotor J; Paz-Carreira J; González-Juanatey C; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2014; 32(2):231-6. PubMed ID: 24295386
[TBL] [Abstract][Full Text] [Related]
3. Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Genre F; Miranda-Filloy JA; López-Mejias R; Carnero-López B; Ochoa R; Rueda J; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2013; 31(4):532-7. PubMed ID: 23484462
[TBL] [Abstract][Full Text] [Related]
4. Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-α therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda J; González-Juanatey C; Llorca J; González-Gay MÁ
Clin Exp Rheumatol; 2013; 31(6):913-8. PubMed ID: 23981480
[TBL] [Abstract][Full Text] [Related]
5. Asymmetric dimethylarginine serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda J; González-Juanatey C; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2013; 31(5):749-55. PubMed ID: 23806325
[TBL] [Abstract][Full Text] [Related]
6. Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Palmou-Fontana N; Gómez-Acebo I; Blanco R; Rueda-Gotor J; Pina T; González-Juanatey C; Llorca J; González-Gay MÁ
Clin Exp Rheumatol; 2014; 32(5):640-6. PubMed ID: 25190453
[TBL] [Abstract][Full Text] [Related]
7. Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Miranda-Filloy JA; López-Mejias R; Genre F; Carnero-López B; Ochoa R; Diaz de Terán T; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2013; 31(4):538-45. PubMed ID: 23711190
[TBL] [Abstract][Full Text] [Related]
8. Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Miranda-Filloy JA; López-Mejias R; Genre F; Carnero-López B; Ochoa R; Diaz de Terán T; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2013; 31(3):365-71. PubMed ID: 23294554
[TBL] [Abstract][Full Text] [Related]
9. Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients.
Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Mijares V; Carnero-López B; Gómez-Acebo I; Dierssen-Sotos T; Remuzgo-Martínez S; Blanco R; Pina T; González-Juanatey C; Llorca J; González-Gay MA
Rheumatol Int; 2015 Dec; 35(12):2069-78. PubMed ID: 26143161
[TBL] [Abstract][Full Text] [Related]
10. TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients.
Miranda-Filloy JA; Llorca J; Carnero-López B; González-Juanatey C; Blanco R; González-Gay MA
Clin Exp Rheumatol; 2012; 30(6):850-5. PubMed ID: 22765845
[TBL] [Abstract][Full Text] [Related]
11. Patients with ankylosing spondylitis and low disease activity because of anti-TNF-alpha therapy have higher TRAIL levels than controls: a potential compensatory effect.
Genre F; López-Mejías R; Rueda-Gotor J; Miranda-Filloy JA; Ubilla B; Carnero-López B; Palmou-Fontana N; Gómez-Acebo I; Blanco R; Pina T; Ochoa R; González-Juanatey C; Llorca J; González-Gay MA
Mediators Inflamm; 2014; 2014():798060. PubMed ID: 24976690
[TBL] [Abstract][Full Text] [Related]
12. Short-term effect of anti-TNF-alpha therapy on nitric oxide production in patients with severe rheumatoid arthritis.
Gonzalez-Gay MA; Garcia-Unzueta MT; Berja A; Vazquez-Rodriguez TR; Miranda-Filloy JA; Gonzalez-Juanatey C; de Matias JM; Martin J; Dessein PH; Llorca J
Clin Exp Rheumatol; 2009; 27(3):452-8. PubMed ID: 19604438
[TBL] [Abstract][Full Text] [Related]
13. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety.
Maksymowych WP; Jhangri GS; Lambert RG; Mallon C; Buenviaje H; Pedrycz E; Luongo R; Russell AS
J Rheumatol; 2002 May; 29(5):959-65. PubMed ID: 12022358
[TBL] [Abstract][Full Text] [Related]
14. Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.
Gonzalez-Gay MA; Vazquez-Rodriguez TR; Garcia-Unzueta MT; Berja A; Miranda-Filloy JA; de Matias JM; Gonzalez-Juanatey C; Llorca J
Clin Exp Rheumatol; 2010; 28(1):56-62. PubMed ID: 20346239
[TBL] [Abstract][Full Text] [Related]
15. IGF-1 and ADMA levels are inversely correlated in nondiabetic ankylosing spondylitis patients undergoing anti-TNF-alpha therapy.
Genre F; López-Mejías R; Rueda-Gotor J; Miranda-Filloy JA; Ubilla B; Villar-Bonet A; Carnero-López B; Gómez-Acebo I; Blanco R; Pina T; González-Juanatey C; Llorca J; González-Gay MA
Biomed Res Int; 2014; 2014():671061. PubMed ID: 25295265
[TBL] [Abstract][Full Text] [Related]
16. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade.
Syngle A; Vohra K; Sharma A; Kaur L
Clin Rheumatol; 2010 Jul; 29(7):763-70. PubMed ID: 20204669
[TBL] [Abstract][Full Text] [Related]
17. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.
Paccou J; Baclé-Boutry MA; Solau-Gervais E; Bele-Philippe P; Flipo RM
J Rheumatol; 2012 Jul; 39(7):1418-23. PubMed ID: 22707611
[TBL] [Abstract][Full Text] [Related]
18. Leptin and adiponectin levels in patients with ankylosing spondylitis. The effect of infliximab treatment.
Derdemezis CS; Filippatos TD; Voulgari PV; Tselepis AD; Drosos AA; Kiortsis DN
Clin Exp Rheumatol; 2010; 28(6):880-3. PubMed ID: 21122270
[TBL] [Abstract][Full Text] [Related]
19. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis.
Arends S; Lebbink HR; Spoorenberg A; Bungener LB; Roozendaal C; van der Veer E; Houtman PM; Griep EN; Limburg PC; Kallenberg CG; Wolbink GJ; Brouwer E
Clin Exp Rheumatol; 2010; 28(5):661-8. PubMed ID: 20822711
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis.
Gonzalez-Gay MA; Garcia-Unzueta MT; Gonzalez-Juanatey C; Miranda-Filloy JA; Vazquez-Rodriguez TR; De Matias JM; Martin J; Dessein PH; Llorca J
Clin Exp Rheumatol; 2008; 26(2):311-6. PubMed ID: 18565254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
